GlobeNewswire

Whitecap Care’s Autism First Joins National Integrated Therapy Provider
11/11/2026
WARRENTON, Va., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Whitecap Care , a leading provider of innovative healthcare services and dedicated to providing advanced, compassionate healthcare services that meet the evolving needs [...]
CHARM Therapeutics and Collaborator Dr. Florian Perner to Present Compelling Data Showing the Potential of Next-Generation Menin Inhibitors to Deliver More Durable Responses for AML at the 8th ASH Annual Meeting
11/11/2026
LONDON – 11 November 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, today [...]
Horizon Europe-funded HERMOD project launches to support Phase 2 development of HER-096 in Parkinson’s disease
11/11/2026
Espoo, Finland, 11 November 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces that the Horizon Europe [...]
AC Immune to Present at Jefferies Global Healthcare Conference 2026
11/11/2026
AC Immune to Present at Jefferies Global Healthcare Conference 2026 Lausanne, Switzerland, November 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded [...]
CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
11/11/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 11, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that studies have commenced with QIMA Life Sciences, a world leading [...]
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
11/11/2026
No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus- [...]
Sinaptica Therapeutics to Host Scientific Symposium at CTAD 2026 Exploring the Role of Brain Network Dysfunction in Alzheimer's Disease
11/11/2026
Leading Alzheimer's researchers Giacomo Koch, Emiliano Santarnecchi and Harald Hampel to examine emerging evidence, biomarkers and therapeutic approaches targeting brain network dysfunction Scientific co-founder Giacomo [...]
Whiskey You Won't Find on Shelves: Breckenridge Distillery Launches the 2 Mile High Whiskey Club
11/11/2026
A Fresh Way to Experience Breckenridge Distillery Through Special Bottlings, Tastings and Behind-The-Scenes Access BRECKENRIDGE, Colo., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , one of the most awarded [...]
Hemab Therapeutics to Participate in Upcoming Investor Conferences
11/11/2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood [...]
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
11/11/2026
Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nurix [...]
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
11/11/2026
A veteran, trained, and certified 17-person sales force, commenced sales operations this week, providing national coverage with customers responsible for approximately 80% of current U.S. ketamine sales Initial supply [...]
Arvinas to Present at Jefferies Global Healthcare Conference
11/11/2026
NEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Applied Biologics Announces Research Collaboration with Dartmouth College Focused on Computational Protein Engineering
11/11/2026
Formal collaboration with Dartmouth’s Thayer School of Engineering will advance computationally guided therapeutic protein design supporting Applied Biologics’ gene therapy development programs SCOTTSDALE, Ariz., Nov. [...]
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
11/11/2026
The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma model A live webcast [...]
Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
11/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to [...]
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
11/11/2026
PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
11/11/2026
D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated by the EMA and European [...]
Dyne Therapeutics to Participate in Upcoming Investor Conference
11/11/2026
WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
11/11/2026
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum